234 related articles for article (PubMed ID: 28181117)
1. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
2. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
3. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
4. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Metra M; Torp-Pedersen C; Swedberg K; Cleland JG; Di Lenarda A; Komajda M; Remme WJ; Lutiger B; Scherhag A; Lukas MA; Charlesworth A; Poole-Wilson PA
Eur Heart J; 2005 Nov; 26(21):2259-68. PubMed ID: 16040619
[TBL] [Abstract][Full Text] [Related]
5. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
6. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
8. Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
Ingram A; Valente M
J Pharm Pract; 2020 Feb; 33(1):96-98. PubMed ID: 29916290
[TBL] [Abstract][Full Text] [Related]
9. The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Petersen HH; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Feb; 20(2):301-307. PubMed ID: 28339659
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
Fröhlich H; Zhao J; Täger T; Cebola R; Schellberg D; Katus HA; Grundtvig M; Hole T; Atar D; Agewall S; Frankenstein L
Circ Heart Fail; 2015 Sep; 8(5):887-96. PubMed ID: 26175538
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure.
Rector TS; Anand IS; Nelson DB; Ensrud KE
J Am Geriatr Soc; 2008 Jun; 56(6):1021-7. PubMed ID: 18384583
[TBL] [Abstract][Full Text] [Related]
12. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
13. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Bauman JL; Talbert RL
J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
[TBL] [Abstract][Full Text] [Related]
15. Differing beta-blocking effects of carvedilol and metoprolol.
Stoschitzky K; Koshucharova G; Zweiker R; Maier R; Watzinger N; Fruhwald FM; Klein W
Eur J Heart Fail; 2001 Jun; 3(3):343-9. PubMed ID: 11378006
[TBL] [Abstract][Full Text] [Related]
16. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
Vardeny O; Detry MA; Moran JJ; Johnson MR; Sweitzer NK
J Cardiovasc Pharmacol; 2008 Dec; 52(6):500-6. PubMed ID: 19034036
[TBL] [Abstract][Full Text] [Related]
17. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
Lymperopoulos A; McCrink KA; Brill A
Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
[TBL] [Abstract][Full Text] [Related]
19. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
Azevedo ER; Kubo T; Mak S; Al-Hesayen A; Schofield A; Allan R; Kelly S; Newton GE; Floras JS; Parker JD
Circulation; 2001 Oct; 104(18):2194-9. PubMed ID: 11684630
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Piccirillo G; Quaglione R; Nocco M; Naso C; Moisè A; Lionetti M; Di Carlo S; Marigliano V
Am J Cardiol; 2002 Nov; 90(10):1113-7. PubMed ID: 12423713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
